|
|
|
|
|
Li,J.G.; Ding,Y.; Huang,Y.M.; Chen,W.L.; Pan,L.L.; Li,Y.; Chen,X.L.; Chen,Y.; Wang,S.Y.; Wu,X.N.. |
Burkitt lymphoma (BL) is a highly malignant non-Hodgkin's lymphoma that is closely related to the abnormal expression of genes. Familial acute myelogenous leukemia related factor (FAMLF; GenBank accession No. EF413001.1) is a novel gene that was cloned by our research group, and miR-181b is located in the intron of the FAMLF gene. To verify the role of miR-181b and FAMLF in BL, RNAhybrid software was used to predict target site of miR-181b on FAMLF and real-time quantitative PCR (RQ-PCR) was used to detect expression of miR-181b and FAMLF in BL patients, Raji cells and unaffected individuals. miR-181b was then transfected into Raji and CA46 cell lines and FAMLF expression was examined by RQ-PCR and western blotting. Further, Raji cells viability and... |
Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Burkitt lymphoma; FAMLF; MiR-181b; Gene expression; RQ-PCR. |
Ano: 2017 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2017000600701 |
| |
|
|
Besbes,S.; Hamadou,W.S.; Boulland,M.L.; Youssef,Y.B.; Achour,B.; Regaieg,H.; Khelif,A.; Fest,T.; Soua,Z.. |
IGH gene rearrangement and IGK-Kde gene deletion can be used as molecular markers for the assessment of B lineage acute lymphoblastic leukemia (B-ALL). Minimal residual disease detected based on those markers is currently the most reliable prognosis factor in B-ALL. The aim of this study was to use clonal IGH/IGK-Kde gene rearrangements to confirm B-ALL diagnosis and to evaluate the treatment outcome of Tunisian leukemic patients by monitoring the minimal residual disease (MRD) after induction chemotherapy. Seventeen consecutive newly diagnosed B-ALL patients were investigated by multiplex PCR assay and real time quantitative PCR according to BIOMED 2 conditions. The vast majority of clonal VH-JH rearrangements included VH3 gene. For IGK deletion, clonal... |
Tipo: Info:eu-repo/semantics/article |
Palavras-chave: IGH gene; IGK gene; B-ALL minimal residual disease (MRD); RQ-PCR. |
Ano: 2017 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2017000100703 |
| |
|
|
|